[go: up one dir, main page]

TW200640877A - Pyrimidine derivatives - Google Patents

Pyrimidine derivatives

Info

Publication number
TW200640877A
TW200640877A TW095114722A TW95114722A TW200640877A TW 200640877 A TW200640877 A TW 200640877A TW 095114722 A TW095114722 A TW 095114722A TW 95114722 A TW95114722 A TW 95114722A TW 200640877 A TW200640877 A TW 200640877A
Authority
TW
Taiwan
Prior art keywords
pyrimidine derivatives
treatment
vascular
visceral
aminocarbonyl
Prior art date
Application number
TW095114722A
Other languages
English (en)
Inventor
Eva Caroff
Olivier Houille
Francis Hubler
Kurt Hilpert
Heinz Fretz
Emmanuel Meyer
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of TW200640877A publication Critical patent/TW200640877A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
TW095114722A 2005-04-28 2006-04-25 Pyrimidine derivatives TW200640877A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2005004578 2005-04-28
IB2005053711 2005-11-10

Publications (1)

Publication Number Publication Date
TW200640877A true TW200640877A (en) 2006-12-01

Family

ID=37075078

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095114722A TW200640877A (en) 2005-04-28 2006-04-25 Pyrimidine derivatives

Country Status (18)

Country Link
US (1) US8048881B2 (zh)
EP (1) EP1893634B1 (zh)
JP (1) JP4955658B2 (zh)
KR (1) KR101310016B1 (zh)
CN (1) CN101166756A (zh)
AR (1) AR056992A1 (zh)
AT (1) ATE538130T1 (zh)
AU (1) AU2006241260A1 (zh)
BR (1) BRPI0608089A2 (zh)
CA (1) CA2604967C (zh)
ES (1) ES2377337T3 (zh)
IL (1) IL186939A0 (zh)
MX (1) MX2007013436A (zh)
NO (1) NO20076094L (zh)
NZ (1) NZ563584A (zh)
RU (1) RU2410393C2 (zh)
TW (1) TW200640877A (zh)
WO (1) WO2006114774A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210635A1 (en) * 2006-03-29 2010-08-19 Takeda Pharmaceutical Company Limited Renin inhibitors
AR063258A1 (es) * 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) * 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CN101663293B (zh) * 2007-04-23 2013-07-31 塞诺菲-安万特股份有限公司 作为p2y12拮抗剂的喹啉-甲酰胺衍生物
KR101178319B1 (ko) * 2007-11-29 2012-09-07 액테리온 파마슈티칼 리미티드 포스폰산 유도체 및 p2y12 수용체 길항물질로서 이들의 용도
JP5504171B2 (ja) * 2007-12-26 2014-05-28 サノフイ P2y12アンタゴニストとしてのヘテロサイクリックピラゾール−カルボキサミド
EP2238127B1 (en) * 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
JP5539235B2 (ja) 2008-02-29 2014-07-02 エボテック・アーゲー アミド化合物、組成物およびそれらの使用
AR071652A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
AR071653A1 (es) * 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
TW200948797A (en) * 2008-04-22 2009-12-01 Daiichi Sankyo Co Ltd 5-hydroxypyrimidine-4-carboxamide compounds
JP5608655B2 (ja) * 2008-09-18 2014-10-15 エヴォテック アーゲー P2x3受容体活性のモジュレーター
KR101114503B1 (ko) * 2008-12-04 2012-02-15 지에스건설 주식회사 부유물 수거장치
KR101694563B1 (ko) 2009-04-08 2017-01-09 액테리온 파마슈티칼 리미티드 Adp 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘
BRPI1015145A2 (pt) 2009-04-22 2018-01-30 Actelion Pharmaceuticals Ltd derivados de tiazol e seu uso como receptores antagonistas de p2y12
WO2011024933A1 (ja) 2009-08-28 2011-03-03 第一三共株式会社 3-(ビアリールオキシ)プロピオン酸誘導体
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus
PL2753606T3 (pl) 2011-09-02 2018-02-28 Purdue Pharma L.P. Pirymidyny jako blokery kanałów sodowych
PT3515924T (pt) 2016-09-22 2022-03-11 Idorsia Pharmaceuticals Ltd Formas cristalinas
JP7580918B2 (ja) 2017-03-15 2024-11-12 イドルシア・ファーマシューティカルズ・リミテッド P2y12受容体アンタゴニストの皮下投与
CN112500354A (zh) * 2020-12-08 2021-03-16 烟台凯博医药科技有限公司 一种4-氯-6-环丙基嘧啶-5-胺的合成方法
WO2025133948A1 (en) 2023-12-21 2025-06-26 Pfizer Inc. Acetyl coa-carboxylase (acc) inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373586A (en) * 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
RU2213744C1 (ru) * 2002-06-27 2003-10-10 Институт органической химии им. Н.Д. Зелинского РАН ПРОИЗВОДНЫЕ АНТРА[2,1-d]ИЗОТИАЗОЛ-3,6,11-ТРИОНА
ES2348942T3 (es) 2002-12-11 2010-12-17 Bayer Schering Pharma Aktiengesellschaft Compuestos de 2-aminocarbonil-quinolina como antagonistas del receptor plaquetario de adenosin difosfato.
AR063258A1 (es) 2006-10-13 2009-01-14 Actelion Pharmaceuticals Ltd Derivados de 2-aminocarbonil-piridina, una composicion farmaceutica que los contiene y su uso en la preparacion de un medicamento para el tratamiento de trastornos vasculares oclusivos.
CL2007003038A1 (es) 2006-10-25 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
KR101178319B1 (ko) 2007-11-29 2012-09-07 액테리온 파마슈티칼 리미티드 포스폰산 유도체 및 p2y12 수용체 길항물질로서 이들의 용도
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
KR101694563B1 (ko) 2009-04-08 2017-01-09 액테리온 파마슈티칼 리미티드 Adp 수용체 길항제로서 6-(3-아자-비시클로〔3.1.0〕헥스-3-일)-2-페닐-피리미딘
BRPI1015145A2 (pt) 2009-04-22 2018-01-30 Actelion Pharmaceuticals Ltd derivados de tiazol e seu uso como receptores antagonistas de p2y12

Also Published As

Publication number Publication date
BRPI0608089A2 (pt) 2009-11-10
MX2007013436A (es) 2008-01-16
AR056992A1 (es) 2007-11-07
WO2006114774A3 (en) 2007-02-08
IL186939A0 (en) 2008-02-09
NZ563584A (en) 2011-03-31
NO20076094L (no) 2008-01-25
RU2007143880A (ru) 2009-06-10
EP1893634A2 (en) 2008-03-05
CA2604967A1 (en) 2006-11-02
AU2006241260A1 (en) 2006-11-02
KR20080004608A (ko) 2008-01-09
EP1893634B1 (en) 2011-12-21
US20080194576A1 (en) 2008-08-14
US8048881B2 (en) 2011-11-01
JP4955658B2 (ja) 2012-06-20
CN101166756A (zh) 2008-04-23
KR101310016B1 (ko) 2013-09-30
CA2604967C (en) 2014-04-01
RU2410393C2 (ru) 2011-01-27
WO2006114774A2 (en) 2006-11-02
ES2377337T3 (es) 2012-03-26
JP2008539224A (ja) 2008-11-13
ATE538130T1 (de) 2012-01-15

Similar Documents

Publication Publication Date Title
TW200640877A (en) Pyrimidine derivatives
MX2009004186A (es) Derivados de 2-fenil-6-aminocarbonil-pirimidina.
MX2009003724A (es) Derivados de 2-aminocarbonil-piridina.
WO2010116328A3 (en) 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines as adp receptor antagonists
MY153749A (en) Phosphonic acid derivates and their use as p2y12 receptor antagonists
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
UA115887C2 (uk) АМІНОЗАМІЩЕНІ ІМІДАЗО[1,2-а]ПІРИДИНКАРБОКСАМІДИ І ЇХ ЗАСТОСУВАННЯ
TW200716140A (en) Treatment of inflammatory conditions
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
EP4480543A3 (en) Chiral diaryl macrocycle and use thereof in the treatment of cancer
WO2006091459A3 (en) Compositions and methods for treating vascular permeability
CL2012000591A1 (es) Compuestos derivados de pirimidina o 1,3,5-triazina, antagonistas de hepcidina; composicion farmaceutica; combinacion farmaceutica util en el tratamiento de desordenes del metabolismo del hierro y los sintomas asociados.
DK2430022T3 (da) 1,2,4-Triazolo[4,3-a]pyridinderivater og deres anvendelse til behandlingen eller forebyggelse af neurologiske og psykiatriske lidelser
WO2007044534A3 (en) Vegf analogs and methods of use
WO2010030813A3 (en) Methods for inhibiting ocular angiogenesis
MY147247A (en) Organic compounds and their uses
DE602005021694D1 (de) Kombinationstherapien gegen multiple toll-like-rezeptoren und ihre verwendung
GB0515353D0 (en) Food
MA32277B1 (fr) Derives de 2-phenyl-4- cyclopropyl-pyrimidine
CL2011000116A1 (es) Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer.
BRPI0808043A2 (pt) Compostos tricíclicos úteis no tratamento de distúrbios de ferro.
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
MY149492A (en) Immunoglobulins directed against nogo
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica